Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
P/E ratio for Pulmonx Corporation (LUNG)
P/E ratio as of 2023: -7.96
According to Pulmonx Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.96. At the end of 2022 the company had a P/E ratio of -5.31.
P/E ratio history for Pulmonx Corporation from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.96 |
| 2022 | -5.31 |
| 2021 | -23.81 |
| 2020 | -76.44 |
| 2019 | -67.26 |
| 2018 | -44.05 |